U.S. market Closed. Opens in 5 hours 54 minutes

CMPS | COMPASS Pathways plc Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.57 - 4.79
52 Week Range 4.05 - 12.75
Beta 1.84
Implied Volatility 197.29%
IV Rank 75.82%
Day's Volume 842,021
Average Volume 662,689
Shares Outstanding 68,409,068
Market Cap 320,154,438
Sector Healthcare
Industry Medical - Care Facilities
IPO Date 2020-09-18
Valuation
Profitability
Growth
Health
P/E Ratio -2.15
Forward P/E Ratio N/A
EPS -2.18
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 186
Country UK
Website CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS's peers: INNV, AGL, USPH, EHAB, ENSG, CCRN, AMED, ACHC, ADUS, SGRY, PNTG, NHC, DVA, FSNUY
*Chart delayed
Analyzing fundamentals for CMPS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see CMPS Fundamentals page.

Watching at CMPS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CMPS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙